Skip to main content
Top
Published in: Reactions Weekly 1/2017

01-12-2017 | Case report

Dabrafenib/pembrolizumab

Hypokalaemia, immune mediated colitis and pneumonitis: case report

Published in: Reactions Weekly | Issue 1/2017

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Li SD, et al. Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. Experimental Hematology and Oncology 6: 29, 6 Nov 2017. Available from: URL: http://doi.org/10.1186/s40164-017-0089-y - USA Li SD, et al. Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. Experimental Hematology and Oncology 6: 29, 6 Nov 2017. Available from: URL: http://​doi.​org/​10.​1186/​s40164-017-0089-y - USA
Metadata
Title
Dabrafenib/pembrolizumab
Hypokalaemia, immune mediated colitis and pneumonitis: case report
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2017
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-39401-3

Other articles of this Issue 1/2017

Reactions Weekly 1/2017 Go to the issue

Case report

Methotrexate

Case report

Glucose

Case report

Tocilizumab

Case report

Melatonin